France Valued fifth globally in terms of overall revenues and enjoying year-on-year growth rates exceeding five percent, the French pharma market is undeniably one of the great global life science powerhouses, playing host to virtually all top-tier, big-brand biopharma. Yet alongside its well-forged reputation for sophisticated healthcare infrastructure, manufacturing excellence, and…

France How can mid-sized European pharmaceutical companies, which lack the scale of both Big Pharma and the major generics players, compete in a country like France? Norgine – a specialist player which turns over around EUR 600 million annually – seems to have hit upon a solution: continuous adaptation.   “What…

France When Marc de Garidel joined AbiVax as CEO in 2023, the firm had very recently teetered on the brink of bankruptcy. Now, less than three short years later, he leads the hottest prospect in European biotech, with a potentially market-leading drug for inflammatory bowel disease nearing regulatory approval. de Garidel…

France France finally has a full budget for 2026, ending months of stasis, and providing a degree of certainty to industry. However, especially for pharma, continual price cuts threaten the sustainability of France as an investment destination, although the reindustrialisation incentives contained with the ‘France 2030’ plan are leading to an…

Europe Writing in the January 2026 edition of DIA’s Global Forum, Samantha Holmes and Fiona Adshead of the Sustainable Healthcare Coalition argue that climate change is already reshaping healthcare and the medicines life cycle, while the pharma sector itself contributes materially to global emissions. Against this backdrop, the European Medicines Agency…

Italy Top recent stories from Italian pharma, including Angelini’s EUR 150 million EU collaboration for European health startups, Chiesi’s new deals for enzyme replacement therapies and gene editing, and why Menarini is setting its sights on the US.   European Union teams up with Angelini to funnel €150M to European health…

France France has long been held up as Europe’s reference point for rare disease care – the first EU country with a national plan, a pioneer of coordinated expert networks, and home to some of the continent’s most influential patient organisations. More than three million French citizens live with one of…

Spain The latest stories from Spain’s booming healthcare and life science industry. Spain still leads Europe for clinical trial numbers, while a recent meeting between Spanish PM Pedro Sánchez and Roche CEO Thomas Schinecker on a new manufacturing agreement speaks to global pharma’s continued focus on the country. In other news,…

Switzerland Natural remedies are on the rise. The USD 80 billion global natural health products market is projected to nearly double by 2033, according to Market Growth Reports, as patients with chronic long-term metabolic, neurological, and inflammatory diseases seek out lower-side-effect botanical interventions to complement or even replace pharmaceuticals.   Health-conscious…

Switzerland Ophthalmology is one of the hottest niches in pharma right now. Investment is flowing in, M&A is up, and a broad cast of actors – from Big Pharma to legacy generics players and biotechs – are looking to get in on a market set to top USD 93.7 billion by…

Switzerland One in six infections worldwide is now resistant to first-line antibiotics, making antimicrobial resistance (AMR) a major global health threat. Despite an extremely challenging commercial landscape, a handful of bold startups continue to innovate in this space, but can they turn the tide?   Microorganisms that develop AMR were directly…

Switzerland Switzerland has become a global leader in cutting-edge cancer research, with close collaborations between research institutions, hospitals, and private industry fostering the next generation of globally impactful cancer innovation.   For instance, in Bellinzona, the capital of the Italian-speaking Ticino canton, the Institute of Oncology Research (IOR) is working with…